studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 807A
Disclosures:
Paul Martin - Advisory Committees or Review Panels: BMS; Grant/Research
Support: Merck, Gilead, Janssen, Abbvie
The following authors have nothing to disclose: Eduardo A. Rodriguez, Cynthia
Levy, Kalyan R. Bhamidimarri
1207
Assessment of serum hepatitis C virus RNA 24 weeks
after the end of treatment using TaqMan PCR is more
relevant than after 12 weeks for predicting sustained
virological response by simeprevir- versus telaprevir-based
triple therapy
Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, Yuki Haga,
Masato Nakamura, Shin Yasui, Makoto Arai, Fumio Imazeki,
Osamu Yokosuka; Department of Gastroenterology and Nephrology,
Chiba University, Graduate School of Medicine, Chiba,
Japan
Background and Aims: Hepatitis C virus (HCV) infection causes
acute and chronic hepatitis and results in cirrhosis and hepatocellular
carcinoma (HCC). Direct-targeting antiviral agents
(DAAs) against HCV with or without peginterferon plus ribavirin
result in higher rates of eradication of this virus and shorter
treatment duration. We examined which is better for predicting
persistent virological response, the assessment of serum HCV
RNA 12 or 24 weeks after the end of treatment for predicting
sustained virological response (SVR12 or SVR 24, respectively)
in patients treated with peginterferon plus ribavirin and HCV
NS3/4A protease inhibitor. Patients and Methods: In all, 145
Japanese patients infected with HCV genotype 1 treated with
peginterferon plus ribavirin with HCV NS3/4A protease inhibitor
were retrospectively analyzed: 59 patients (57.6 years;
male, 42; and IL28B rs8099917TT, 40) and 86 patients (60.8
years; male, 42; and IL28B rs8099917TT, 58) were treated
by telaprevir- and simeprevir-including regimens, respectively.
Written informed consent was obtained from all patients, and
this study conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Ethics Committee
of Chiba University, School of Medicine (No.523 and
No.1462). HCV RNA was measured by TaqMan HCV Test,
version 2.0, real-time PCR assay. IL28B rs8099917 was analyzed
by TaqMan SNP assay. SVR12 and SVR24, respectively,
were defined as HCV RNA negativity at 12 week and 24 week
after stopping treatment. Results: Total SVR rates were 78.0%
and 70.7%, in telaprevir and simeprevir groups, respectively.
In telaprevir group, SVR rates of treatment-naïve, previous-treatment
relapsers and others were 76.7%, 87.0% and 50.0%,
respectively. In simeprevir group, SVR rates of treatment-naïve,
previous-treatment relapsers and others were 75.0%, 100%
and 25.0%, respectively. In telaprevir group, all 46 patients
with SVR12 finally achieved SVR24. In simeprevir group, only
4 (7.1%) of total 56 patients with SVR12 achieved SVR24, and
these 4 patients were all previous-treatment relapsers (67.5
years; male, 2; and IL28rs8099917TT, 2). Conclusion: SVR12
were suitable for predicting persistent virological response in
almost cases. In simeprevir-including regimens, SVR12 could
not always predict persistent virological response. Clinician
should use SVR24 for predicting persistent virological response
in the use of DAA treatment for a group of real-world patients
chronically infected with HCV.
Disclosures:
Tatsuo Kanda - Grant/Research Support: MSD K.K.; Speaking and Teaching:
AJINOMOTO PHARMACEUTICALS CO., LTD, CHUGAI PHARMACEUTICAL
CO., LTD, GlaxoSmithKlein, BMS, Jansen, Daiichisankyo; Stock Shareholder:
Mitsubishi Tanabe Pharma
Osamu Yokosuka - Grant/Research Support: Chugai, Taiho, Bristol Myers,
Takeda
The following authors have nothing to disclose: Shingo Nakamoto, Reina Sasaki,
Yuki Haga, Masato Nakamura, Shin Yasui, Makoto Arai, Fumio Imazeki
1208
Reduced Survival in Elderly Liver Transplant Recipients:
How Old is Too Old?
Nae-Yun Heo 1,2 , Ajitha Mannalithara 1 , Prowpanga Udompap 1 ,
Donghee Kim 1 , Waldo Concepcion 3 , Carlos O. Esquivel 3 , W.
Ray Kim 1 ; 1 Division of Gastroenterology and Hepatology, Stanford
University School of Medicine, Stanford, CA; 2 Department
of Internal Medicine, Inje University College of Medicine, Busan,
Korea (the Republic of); 3 Department of Surgery, Stanford University
School of Medicine, Stanford, CA
Background/Aims: Liver transplantation (LTx) is increasingly
performed in patients over 65 years of age, an age group
traditionally considered to be high risk. Prognostic models specifically
designed to predict post-LTx outcome in elderly patients
may help select optimal candidates. Methods: Records of all
adult (>18 years) LTx recipients were extracted from the Organ
Procurement and Transplantation Network (OPTN) database
for 2004-2013. After exclusion of recipients of multi-organ or
repeated LTx, recipients were divided into three groups: